Aquestive Therapeutics, Inc. (AQST): Operating Cash Flow
-$52.43M
Year ended 2025-12-31
-$45.37M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$52.43M | n/m | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | -$35.76M | n/m | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | -$6.38M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$9.82M | n/m | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | -$32.98M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$45.46M | n/m | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | -$60.21M | n/m | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | -$12.99M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $5.82M | n/a | 2019-03-14, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.43M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$4.99M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $110.19M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $57.67M | -68.7% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | -$187.49M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$13.36M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
Compare AQST, CPIX, XLO, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗